HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat has maintained a Buy rating on Xeris Biopharma Holdings (NASDAQ:XERS) and increased the price target from $5.5 to $6.

March 07, 2024 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Oren Livnat maintains a Buy rating on Xeris Biopharma Holdings and raises the price target from $5.5 to $6.
The upgrade in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the company's future performance, potentially leading to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100